Author name: Swaraj Paul Barooah

.

Time to Act on ACTA

The shroud of secrecy around the Anti-Counterfeiting Trade Agreement (ACTA) has arguably become a little more transparent during the past 2 years of negotiation, albeit due more to leaks more than positive acts towards transparency. (Readers may recall our previous posts on ACTA) Civil societies, nonprofits and blogs have also played an important part in this by constantly questioning the suspicious nature of its negotiations, not to mention the (leaked) provisions themselves. The agreement, which is supposed to be completed […]

Time to Act on ACTA Read More »

SpicyIP Tidbit: WHO is Looking after Flu Scares?

An Inter-Governmental meeting this week of the Executive Board Members of the WHO, saw concerns on several different issues being discussed. Regarding a way towards an influenza framework, it was agreed that they would try to complete a framework for dealing with influenza in time for the World Health Assembly in May later this year. One of the main issues discussed was that of development and distribution of vaccines. The usual developed – developing line roughly divided the groups, with

SpicyIP Tidbit: WHO is Looking after Flu Scares? Read More »

Access to Food now an IP issue?

Aggressive patent protection is now apparently leading two US based Non profit organizations to challenge patents of nut based product “Plumpy’nut”, owned by Malaunay, France-based company, Nutriset. The two US nonprofits want to produce a high-protein, nut based food product which is extremely beneficial for the malnourished/undernourished. The product provides 500 calorie dosages of vitamins and minerals, and several health experts have agreed that this type of product is greatly beneficial in treating severely malnourished children. (image taken from here)

Access to Food now an IP issue? Read More »

Fair comments on "Fake Drugs" ?

Recently, two analysts from International Policy Network, London wrote a piece entitled “Fake scare about Fake drugs” alleging that claims of ‘over-protection of intellectual property rights’ and at the same time, ‘not protecting patients interests’, which are being used by developmental NGOs (in their words, “Oxfam and other activist NGOs”), are false as well as dangerous. I would like to take this chance to react to their article, published by IP-Watch, as it contains a number of disputable, if not

Fair comments on "Fake Drugs" ? Read More »

Liberalization of Foreign Technology Agreement Policy

There is good news for the Indian technological industry. The Government of India yesterday (17th Dec), issued a Press Release stating that it has reviewed its foreign technology agreement policy to no longer require government approval, with immediate effect. The prior policy freely allowed payments and remittances up to a lumpsum fee of $2million and royalty payments of 5% on domestic sales and 8% on exports. Payments above this required regulatory approval.
 The new policy removes any such restrictions on

Liberalization of Foreign Technology Agreement Policy Read More »

See-sawing at Copenhagen

With hardly any time remaining for discussions at ‘Hopenhagen’, the position of IP in the treaty text continues to remain ambiguous, see-sawing between a number of IP references being mentioned (1st draft), to IP not being mentioned explicitly at all (2nd draft) , and back to IP being mentioned again in the 3rd draft text (provided by IP-Watch here) on the development and transfer of technology at the 7-18th December United Nations Climate Change Conference (COP15) being held at Copenhagen.

See-sawing at Copenhagen Read More »

Spicy IP Jobs: Research position at Neuchatel University

As part of the EU-funded Access to Pharmaceuticals (ATP) consortium, The Institute of Health Law at the University of Neuchatel, Switzerland is seeking to fill a position of a Scientific Collaborator in an international research project on IP and Access to Pharmaceutical Products and for running the part on Compulsory Licensing, in the framework of the EU 7th Framework Programme (FP7). The ATP consortium recognizes the importance of equitable access to pharmaceuticals, especially in developing countries, and as such, focuses

Spicy IP Jobs: Research position at Neuchatel University Read More »

OSDD still well on track

Readers may remember the Open Source Drug Discovery (OSDD) programme launched by the Council of Scientific and Industrial Research (CSIR) which we had blogged about a little over a year ago here. Started in September, 2008, the OSDD is a consortium of Indian as well as global researchers who are currently getting together to find a cure to Tuberculosis. As MIT’s Technology Review notes, November 23rd marked a red-letter day for OSDD since after about 14 months since its launch,

OSDD still well on track Read More »

India approaches WTO as yet another seizure takes place

Even as India and other developing countries are on the verge of filing a formal complaint at the WTO with regard to the 17 highly controversial seizures which have occurred since late last year (which we have posted several times on here) yet another consignment of drugs has been seized last month on grounds of patent violation, this time in France. The consignment was of 1.74 million pills of the anti-platelet drug clopidogrel from Mumbai-based Macleods Pharma and was destined

India approaches WTO as yet another seizure takes place Read More »

Uncertainty at Bangkok Climate Change meet

The recent UN session on Climate change which ran from 28th September to 9th October in Bangkok, highlighted what has become an all too familiar scenario of a clash of interests between developed and developing countries leading to failed talks. The Bangkok meeting brought together delegates from over 180 countries to deal with the issue of the expiry of the Kyoto Protocol 2012 deadline for reduction of carbon emissions and with the goal of refining a 200 page draft agreement

Uncertainty at Bangkok Climate Change meet Read More »

Scroll to Top